• 1
    Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10231030.
  • 2
    Coiffer B,Lepage E,Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 3
    Pfreundschuh M,Trumper L,Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International (Mint) Group. Lancet Oncol. 2006; 7: 379391.
  • 4
    Philip T,Guglielmi C,Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL. N Engl J Med. 1995; 333: 15401545.
  • 5
    Vose JM,Anderson JR,Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1993; 11: 18461851.
  • 6
    Hamlin PA,Zelenetz AD,Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003; 102: 19891996.
  • 7
    Zinzani PL,Magagnoli M,Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999; 10: 11411143.
  • 8
    Jerusalem G,Beguin Y,Fassotte MF, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999; 94: 429433.
  • 9
    Schot BW,Zjilstra JM,Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007; 109: 486491.
  • 10
    Filmont JE,Gisselbrecht C,Cuenca X, et al. The impact of pre and post transplantation positron emission tomography using 18-fluorodeoxyglucose on poor prognosis lymphoma patients undergoing autologous stem cell trans-plantation. Cancer. 2007; 110: 13611369.
  • 11
    Svoboda J,Andreadis C,Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006; 38: 211216.
  • 12
    Spaepen K,Stroobants S,Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003; 102: 5359.
  • 13
    Cremerius U,Fabry U,Wildeberger JE, et al. Pretransplantation positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose (FDG) predicts outcome in patients treated with high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002; 30: 103111.
  • 14
    Zinzani PL.Tani M,Molinari AL, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica. 2002; 87: 816821.
  • 15
    Mikhaeel NG,Timothy AR,O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma—comparison with CT. Leuk Lymphoma. 2000; 39: 543553.
  • 16
    Cheson BD,Horning SJ,Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 12441249.
  • 17
    Kaplan EL,Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 18
    Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187220.
  • 19
    Spaepen K,Stroobants S,Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002; 13: 13561363.
  • 20
    Mikhaeel NG,Hutchings M,Fields PA, et al. FDG-PET after 2 to 3 cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005; 16: 15141523.
  • 21
    Haioun C,Itti E,Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005; 106: 13761381.